Kyungho Jang
Research Subjects
Research Interests
Kyungho Jang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Amandine Manon
Certara, Inc., Durham, North Carolina
1 shared publication - Francine Attié de Castro
Certara, Paris 75008, France
1 shared publication - Howard Lee
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea
1 shared publication - Hyewon Chung
Department of Clinical Pharmacology and Toxicology, Korea University Guro Hospital, Seoul 08308, Korea
1 shared publication - Jae-Yong Chung
Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Bundang Hospital Gyeonggi‐do Korea
1 shared publication - Jangsoo Yoon
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 31 (3) , 125-130
What goes in the regulatory clinical pharmacology package for an oncolytic virus?
Yum SY, et al. Transl Clin Pharmacol. 2023 Sep;31(3):125-130. https://doi.org/10.12793/tcp.2023.31.e14
- 1 January 2023
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 31 (3) , 125-130
Open AccessWhat goes in the regulatory clinical pharmacology package for an oncolytic virus?
Yum SY, et al. Transl Clin Pharmacol. 2023 Sep;31(3):125-130. https://doi.org/10.12793/tcp.2023.31.e14
- Open Access
- 16 June 2020
- Published by S. Karger AG in Obesity Facts
- Vol. 13 (3) , 375-385
Altered Gene Expression Profiles in Peripheral Blood Mononuclear Cells in Obese Subjects
Introduction: Gene expression profiles in human peripheral blood mononuclear cells (PBMCs) may act as a useful tool to better understand obesity. We investigated gene expression levels in PMBCs for possible differences between obese and non-obese subjects (19–55 years) and evaluated correlations between gene expression in PBMCs and clinical obesity indices. Methods: Body weight, BMI, fat amount, fat percentage, waist/hip ratio, leptin, and adiponectin levels were determined in 30 obese and 20 non-obese subjects. Expression levels of 19 genes, which were differentially expressed by clinical obesity indices in the PBMCs of high fat-fed rats, were determined in their PBMCs using real-time PCR. Results: The expression of 9 of 19 previously selected genes was significantly correlated with one or more clinical obesity indices. Both TFEC and CCL2 expression were negatively correlated with BMI, fat amount, fat percentage, waist/hip ratio, and leptin concentration. Similarly, TNFAIP2, VCAN, ASSI, IRF1, and HK3 expression negatively correlated with some clinical obesity indices, such as TNFAIP2 for BMI, fat amount, fat percentage, and waist/hip ratio, VCAN for fat amount, fat percentage, and waist/hip ratio, ASS1 for BMI and fat amount, IRF1 for BMI, fat amount, and fat percentage, and HK3 for fat amount. In contrast, both TNF-α and LPL expression were positively correlated with waist/hip ratio. Conclusion: We identified 9 of 19 genes in human PBMCs that significantly correlated with one or more clinical obesity indices. Because these genes have a mechanistic basis for the development or progression of obesity and its metabolic derangements, they may help to determine possible underlying mechanisms for obesity.
- 16 June 2020
- Published by S. Karger AG in Obesity Facts
- Vol. 13 (3) , 375-385
Open AccessAltered Gene Expression Profiles in Peripheral Blood Mononuclear Cells in Obese Subjects
Introduction: Gene expression profiles in human peripheral blood mononuclear cells (PBMCs) may act as a useful tool to better understand obesity. We investigated gene expression levels in PMBCs for possible differences between obese and non-obese subjects (19–55 years) and evaluated correlations between gene expression in PBMCs and clinical obesity indices. Methods: Body weight, BMI, fat amount, fat percentage, waist/hip ratio, leptin, and adiponectin levels were determined in 30 obese and 20 non-obese subjects. Expression levels of 19 genes, which were differentially expressed by clinical obesity indices in the PBMCs of high fat-fed rats, were determined in their PBMCs using real-time PCR. Results: The expression of 9 of 19 previously selected genes was significantly correlated with one or more clinical obesity indices. Both TFEC and CCL2 expression were negatively correlated with BMI, fat amount, fat percentage, waist/hip ratio, and leptin concentration. Similarly, TNFAIP2, VCAN, ASSI, IRF1, and HK3 expression negatively correlated with some clinical obesity indices, such as TNFAIP2 for BMI, fat amount, fat percentage, and waist/hip ratio, VCAN for fat amount, fat percentage, and waist/hip ratio, ASS1 for BMI and fat amount, IRF1 for BMI, fat amount, and fat percentage, and HK3 for fat amount. In contrast, both TNF-α and LPL expression were positively correlated with waist/hip ratio. Conclusion: We identified 9 of 19 genes in human PBMCs that significantly correlated with one or more clinical obesity indices. Because these genes have a mechanistic basis for the development or progression of obesity and its metabolic derangements, they may help to determine possible underlying mechanisms for obesity.
- 1 February 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (2) , 295-304
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State
- 1 February 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (2) , 295-304
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State
- 22 February 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (9) , 1104-1110
Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects
Age‐related physiological changes are known to alter the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs. Metformin is commonly used as first‐line medication for management of diabetes in elderly patients. However, the PK and PD of metformin have not been sufficiently studied in elderly subjects. Here, 12 elderly subjects, aged 65 to 85 years, and 20 younger healthy volunteers were orally administered 750 mg of metformin 2 hours after dinner, followed by administration of a second dose (500 mg) 12 hours later. An oral glucose tolerance test (OGTT) was performed 2 hours after the second dose, with 75 g of glucose administered. Blood samples were collected at specific time points after the second metformin dose for the assessment of PK and the glucose‐lowering effect of metformin. Elderly subjects exhibited 1.7 and 2.0 times higher average Cmax and AUC∞ than the younger subjects, respectively (P = .007 and .001, respectively), and t1/2 was comparable between the elderly and younger subjects. However, relative glucose level changes from baseline after metformin administration tended to be lower in elderly subjects. Systemic exposure to metformin was elevated by 50% or more in elderly subjects, whereas the glucose‐lowering effect was similar compared to younger subjects after 2 doses of metformin.
- 22 February 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (9) , 1104-1110
Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects
Age‐related physiological changes are known to alter the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs. Metformin is commonly used as first‐line medication for management of diabetes in elderly patients. However, the PK and PD of metformin have not been sufficiently studied in elderly subjects. Here, 12 elderly subjects, aged 65 to 85 years, and 20 younger healthy volunteers were orally administered 750 mg of metformin 2 hours after dinner, followed by administration of a second dose (500 mg) 12 hours later. An oral glucose tolerance test (OGTT) was performed 2 hours after the second dose, with 75 g of glucose administered. Blood samples were collected at specific time points after the second metformin dose for the assessment of PK and the glucose‐lowering effect of metformin. Elderly subjects exhibited 1.7 and 2.0 times higher average Cmax and AUC∞ than the younger subjects, respectively (P = .007 and .001, respectively), and t1/2 was comparable between the elderly and younger subjects. However, relative glucose level changes from baseline after metformin administration tended to be lower in elderly subjects. Systemic exposure to metformin was elevated by 50% or more in elderly subjects, whereas the glucose‐lowering effect was similar compared to younger subjects after 2 doses of metformin.